Drug Formulary Review Archives – February 1, 2005
February 1, 2005
View Issues
-
VHA consultants strive to improve pharmacy position in member hospitals
A national health cooperative is using a team of in-house consultants to help increase the efficiency of pharmacy departments in member hospitals. -
Pharmacists urged to ask patients about CAM use
Health trend researchers are urging pharmacists more than ever to ask patients about possible use of complementary and alternative medicine (CAM). Not only are cost concerns driving more lower-income, uninsured patients to try alternative therapies, but many of these patients arent telling their health care providers about these treatments. -
Aromatase inhibitor shows promise in reducing breast cancer recurrence
New research shows that aromatase inhibitor anastrozole (Arimidex) may be more effective than tamoxifen in preventing recurrence of breast cancer. -
FDA recommends limiting COX-2 inhibitors use
The questions continue about the safety of COX-2 selective nonsteroidal anti-inflammatory drugs (NSAIDs). -
News Briefs
FDA: Gefitinib (Iressa) does not prolong survival; The FDA adds warnings to bevacizumab (Avastin) label; Computer entry cases medication errors; Americans still confident about prescription drugs. -
Drug Criteria & Outcomes: Duloxetine (Cymbalta) Formulary Evaluation
Part 2: Clinical Trial Summary, Treatment of Peripheral Neuropathy, Conclusion/Recommendation. -
In the Pipleline
Kosan Biosciences has announced that the FDA has granted the companys anticancer compound 17-allylamino-17-demethoxy-geldanamycin (17-AAG), an analog of the polyketide geldanamycin, orphan drug status for the treatment of multiple myeloma.